Home | Publications | Prescription Drugs place holder
place holder place holder

Prescription Drugs

Textbook of Interventional Cardiovascular Pharmacology


Publication Date   April 2007
Publisher   Informa Healthcare
Product Type   Book
Pages   528
ISBN Number   978-1-84184-438-1
Product Code   IFH166
Ask a question about this product?

Price £140.00

approximately: $262 | €178

Summary


While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations.

This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology.

Content


  • Part I. Systemic and Endoluminal Therapy
    • 1. Principles of Antithrombotic Therapy
    • 2. Principles of Antiplatelet Therapy
    • 3. Glycoprotein Iib/Iiia Inhibitors
    • 4. Adp( Adenosine Diphoshate) Receptor Inhibitors
    • 5. Phosphodiesterase Inhibitors
    • 6. Heparin, Low Molecular Weight Heparin
    • 7. Direct Thrombin Inhibition in Percutaneous Coronary Intervention
    • 8. Parenteral Direct Antithrombin
    • 9. Oral Antithrombin Drugs
    • 10. Rationale for Direct Factor Xa Inhibitors in Acute Coronary Syndromes
    • 11. Combined Anticoagulant and Antiplatelet Therapy
    • 12. Fibrinolytic Therapy
    • 13. Resistance to Anti-Platelet Drugs
    • 14. Lipid-Lowering Agents
    • 15. Antihypertensive Agents
    • 16. Homocysteine Regulators
    • 17. Role of Systemic Anti-Restenotic Drugs and Results of Current Clinical Trials
    • 18. Role of Systemic Antineoplasic Drugs in The Treatment of Restenosis after Percutaneous Stent Implantation
    • 19. Antioxidants
    • 20. Iron Chelation: Deferoxamine and beyond
  • Part II. Local Therapy
    • 21. Stent-Mediated Local Drug Delivery
    • 22. Brachytherapy
    • 23. The Application of Controlled Drug Delivery Principles to The Development of Drugeluting Stents
    • 24. Polymers and Drug-Eluting Stents
    • 25. The Utilization of Antiproliferative and Antimigratory Compounds for The Prevention of Restenosis
    • 26. Anti-Inflammatory Drugs, Sirolimus, and Inhibition of Tor and Its Effect on Vascular Diseases
    • 27. Anti-Migratory Drugs and Mechanisms of Action
    • 28. Anti-Angiogenesis Drugs and Mechanism of Action
    • 29. Vasculoprotective Approach for Restenosis/Nitric Oxide Donors/Estradiols
    • 30. Vascular Endothelial Growth Factor (Vegf)
    • 31. Gene Therapy
    • 32. Antisense Approach
    • 33. Principles of Pdt
  • Part III. Therapeutic Angiogenesis
    • 34. Angiogenesis and Myogenesis
    • 35. Growth Factor Therapy
    • 36. Cell Transplantation for Cardiovascular Repair
    • 37. Clinical Trials in Cellular Therapy
  • Part IV. Adjunctive Pharmacotherapy
    • 38. The Heart Failure Patient
    • 39. The Acute Coronary Syndrome Patient
    • 40. Cardiovascular Interventional Pharmacology in The Diabetic Patient
    • 41. Atrial Fibrillation during Catheterisation
    • 42. Contrast-Induced Nephropathy after Pci
    • 43. Erectile Dysfunction
    • 44. Peripheral Arterial Disease
    • 45. Pharmacotherapy Peri-Percutaneous Coronary Intervention
    • 46. Drug Interaction in Patients Undergoing Cardiovascular and Vascular Interventions
    • 47. Newer Pharmacologic Approaches Targeting Receptors and Genes
    • 48. Pharmacologic Management of Patients with Cto Interventions
  • Part V. Non-Coronary Interventions
    • 49. Carotid Stenting
    • 50. Anticoagulants in Peripheral Vascular Interventions
    • 51. Repair of Aaas
    • 52. Interventions for Structural Heart Disease
    • 53. Pharmacological Use of Ethanol for Myocardial Septal Ablation